Pharmaceutical - Pharmaceutical, CNS Diseases

Filter

Popular Filters

MS market to reach $20 billion in 2023 boosted by five new therapies

MS market to reach $20 billion in 2023 boosted by five new therapies

08-08-2014

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will…

CNS DiseasesEuropeImmunosuppressantsJapanMarkets & MarketingMSPharmaceuticalUSA

Lundbeck’s 2nd-qtr sales drop 24% in the US but European territories help it maintain 2014 outlook

Lundbeck’s 2nd-qtr sales drop 24% in the US but European territories help it maintain 2014 outlook

07-08-2014

Danish CNS drug specialist Lundbeck has seen sales fall from 3.35 billion kroner ($364 million) in the…

AzilectBrintellixCipralexCNS DiseasesCNS drug specialistDenmarkFinancialLundbeckOnfiPharmaceuticalSabrilValbyXenazine

PTC Therapeutics given conditional approval in EU for Translarna in muscular dystrophy

PTC Therapeutics given conditional approval in EU for Translarna in muscular dystrophy

04-08-2014

Biopharmaceutical company PTC Therapeutics has received conditional marketing authorization from the…

CNS DiseasesDiseaseDuchenne muscular dystrophyEuropeGenetic engineeringGeneticsMuscular dystrophyPharmaceuticalPTC TherapeuticsRegulationTranslarna

Biogen and AbbVie release Phase III data for MS treatment

Biogen and AbbVie release Phase III data for MS treatment

17-06-2014

US biotech firm Biogen Idec and US drugmaker AbbVie have announced positive top-line results from the…

AbbVieBiogen IdecCNS DiseasesdaclizumabPharmaceuticalResearchUSA

US FDA grants Edison Pharmaceuticals’ EPI-743 orphan status for Leigh Syndrome

US FDA grants Edison Pharmaceuticals’ EPI-743 orphan status for Leigh Syndrome

09-06-2014

The US Food and Drug Administration has granted orphan drug status to privately-held US pharma company…

CNS DiseasesEdison PharmaceuticalsEPI-743PharmaceuticalRegulationUSA

Pfizer agrees to pay $325 million over Neurontin

Pfizer agrees to pay $325 million over Neurontin

03-06-2014

US pharma giant Pfizer has agreed a $325 million settlement over a trial regarding the marketing of Neurontin…

CNS DiseasesLegalNeurontinPfizerPharmaceuticalUSA

Lundbeck partners with Nanomerics for drug delivery collaboration

Lundbeck partners with Nanomerics for drug delivery collaboration

30-04-2014

UK-based drug delivery company Nanomerics, a spin out of the University College London, has announced…

Brain cancerBrain tumorCNS DiseasesDementiaLundbeckMedicineNeurologicalPharmaceuticalResearchUKUniversity College London

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

Forest Labs reports rise in sales and EPS doubles in second quarter results

23-10-2013

Forest Laboratories has released its second quarter results which showed that net sales for the quarter…

BystolicCNS DiseasesDalirespFinancialForest LaboratoriesLinzessNamendaNorth AmericaPharmaceuticalRespiratory and PulmonarySavellaTeflaroTudorza PressairViibryd

Novartis MS drug Gilenya leads to reduction in brain volume drug

Novartis MS drug Gilenya leads to reduction in brain volume drug

04-10-2013

Novartis has revealed new data indicating that continued treatment with Gilenya led to a reduction in…

CNS DiseasesEuropeGilenyaNovartisPharmaceuticalResearch

Back to top